Zonisamide Prophylaxis in Refractory Pediatric Headache

Pakalnis, Ann; Kring, Donna

doi:10.1111/j.1526-4610.2006.00455.x

Cited by 49 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is limited information, largely from open label clinical trials, suggesting that zonisamide may be effective in migraine prophylaxis in adults and children (Smith, 2001;Krusz, 2001b;Bigal et al, 2002;Drake et al, 2004;Pakalnis and Kring, 2006;Ashkenazi et al, 2006). Taken together with the available base of information on zonisamide, a case can be made that further study of the drug in controlled trials is warranted.…”

Section: Zonisamidementioning

confidence: 99%

“…Evidence from double blind randomized placebo-controlled studies also support the effectiveness of gabapentin in migraine prophylaxis (Di Trapani et al, 2000;Mathew et al, 2001) and it is considered a third line agent by BASH. Less robust clinical studies have indicated that carbamazepine (Rompel et al, 1970), lamotrigine (Steiner et al, 1997;D'Andrea et al, 1999;Lampl et al, 2005;Gupta et al, 2007), zonisamide (Drake et al, 2004;Pakalnis and Kring, 2006) and levetiracetam (Brighina et al, 2006) may also be effective in the treatment of migraine. A metaanalysis by the Cochrane Collaboration confirmed that as a class AEDs reduce migraine frequency and are relatively well tolerated (Chronicle and Mulleners, 2004).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antiepileptic drugs and migraine

Rogawski

2008

Innovative Drug Development for Headache Disorders

View full text Add to dashboard Cite

Section: Zonisamidementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antiepileptic drugs and migraine

Rogawski

2008

Innovative Drug Development for Headache Disorders

View full text Add to dashboard Cite

“…In a retrospective chart review (class IV) of refractory headache patients (6 with episodic migraine, 2 with chronic migraine, 4 with chronic tension-type headache) treated with zonisamide (mean dose of 5.7 mg/kg/day), 8 out of 12 patients showed a positive response to zonisamide (450% reduction in headache frequency when compared to baseline) [Pakalnis and Kring, 2006]. Of the 4 non-responder patients, 3 had chronic tension-type headache.…”

Section: Zonisamidementioning

confidence: 99%

Antiepileptic drugs in the preventive treatment of migraine in children and adolescents

Vollono

Ferraro

Valeriani

2007

Drug Development Research

View full text Add to dashboard Cite

Migraine prevalence in childhood ranges from 2.7 to 10% causing a significant impact on quality of life. No drugs are currently approved for use in the prevention of pediatric migraine. Antiepileptic drugs such as valproate and topiramate have been approved for the preventive treatment of migraine in adults. The present study aimed at reviewing evidence on the efficacy and safety of antiepileptic drugs in the preventive treatment of migraine in children and adolescents. We searched PubMed from 1988 to May 2007 and reviewed, abstracted, and classified relevant literature. Thirteen studies were reviewed. Data from randomized controlled trials are available only for valproate and topiramate. They show that both topiramate and valproate are effective in reducing headache frequency, intensity, and duration. As for safety and tolerability, topiramate is well tolerated, while there are insufficient data regarding the tolerability of valproate. Open-label or retrospective studies suggest that levetiracetam, zonisamide, and gabapentin are effective, but further evidence is warranted to confirm these data. © 2007 Wiley-Liss, Inc

show abstract

“…It was studied retrospectively in 12 pediatric headache patients with mixed headache types (average age 13.5 years) [Pakalnis and Kring, 2006]. Headaches were reduced from baseline and the drug side effects were mild, namely weight loss and behavioral changes.…”

Section: Anti-epileptic Drugsmentioning

confidence: 99%

Preventive therapies of pediatric migraine

Pakalnis

2007

Drug Development Research

Self Cite

View full text Add to dashboard Cite

Migraine headaches are a common neurological condition in children and adolescents. Frequent headaches can negatively impact a child's school attendance and leisure activities. Secondary effects can be disruptive to family dynamics with parental work absences and stress involved in caring for an ill child. Preventive therapies for pediatric migraine have not been well studied and reproducible data from clinical trials is notable for its paucity in the neurological literature. Antihistamines, B-blockers, and other older therapies have limited data. Many of the newer therapies have been developed from antiepileptic drugs, which have reproducible safety data from pediatric epilepsy trials. This has generated further interest in evaluation of these newer agents such as topiramate and levetiracetam. However, for children and adolescents who will require preventive therapy to decrease migraine frequency; there is little evidence available for clinicians from randomized controlled trials. Drug Dev Res 68: 350-354, 2007.

show abstract

Zonisamide Prophylaxis in Refractory Pediatric Headache

Abstract: Zonisamide had some efficacy in headache reduction. It was well tolerated with only minor side effects. Further prospective studies with zonisamide are warranted in refractory pediatric headache patients.

Cited by 49 publications

References 12 publications

Antiepileptic drugs and migraine

Antiepileptic drugs and migraine

Antiepileptic drugs in the preventive treatment of migraine in children and adolescents

Preventive therapies of pediatric migraine

Contact Info

Product

Resources

About